LY310762

Research use only, not for human use.

LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM.

LY310762 is a 5-HT1D antagonist with Ki of 249 nM, having a weaker affinity for 5-HT1B receptor.

LY310762 (0.01-1 μM) shows potentiation of potassium-induced [3H]5-HT outflow from guinea pig cortical slices with an EC50 value of 31 nM.LY310762 (10 μM) significantly but not completely blocks the extent of sumatriptan-induced decrease in EPSCs (excitatory postsynaptic potential).

LY310762 (10 mg/kg; i.p.; single) significantly increases the extracellular 5-HT concentration produced by Fluoxetine (selective serotonin re-uptake inhibitor) in vivo.LY310762 (1 mg/kg; i.v.; single) abolishes 5-HT vasodilator effects in phenylephrine-infusion rats model. Animal Model:Dunkin Hartley guinea pigs (female; 350-400 g, Harlan).Dosage:10 mg/kg Administration:Intraperitoneal injection; single Result:Produced a further significant enhancement in the 5-HT response to fluoxetine.Animal Model:Male Wistar rats (270-330 g; phenylephrine-infusion rats model).Dosage:1 mg/kg Administration:Intravenous injection; single Result:Completely abolished 5-HT vasodilator effects.

LY310762 | LY 310762 | LY-310762

Others

Antioxidant

5-HT1D

Neurological Disease

——

192927-92-7

430.94

C24H27FN2O2·HCl

>98% (HPLC)

DMSO : ≥ 44 mg/mL; 102.10 mM

Cl.CC1(C)C(=O)N(CCN2CCC(CC2)C(=O)c2ccc(F)cc2)c2ccccc12

1-(2-(4-(4-fluorobenzoyl)piperidin-1-yl)ethyl)-3,3-dimethylindolin-2-one hydrochloride

(-20℃)

With Ice Pack

≥ 2 years